BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Wood AJ, Kasireddy V, Chitturi S, Walsh JP. Insulinoma Presenting With Postprandial Hypoglycemia in a Pregnant Woman With MEN-1. JCEM Case Reports 2022;1. [DOI: 10.1210/jcemcr/luac015] [Reference Citation Analysis]
2 Ye Z, Chen H, Ji S, Hu Y, Lou X, Zhang W, Jing D, Fan G, Zhang Y, Chen X, Zhuo Q, Chen J, Xu X, Yu X, Xu J, Qin Y, Gao H. MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors. Acta Biochim Biophys Sin (Shanghai) 2022;54:1599-609. [PMID: 36604142 DOI: 10.3724/abbs.2022162] [Reference Citation Analysis]
3 Băicoianu-Nițescu LC, Gheorghe AM, Carsote M, Dumitrascu MC, Sandru F. Approach of Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome-Related Skin Tumors. Diagnostics (Basel) 2022;12. [PMID: 36428828 DOI: 10.3390/diagnostics12112768] [Reference Citation Analysis]
4 Boharoon H, Grossman A. A New Medical Therapy for Multiple Endocrine Neoplasia Type 1? touchREV Endocrinol 2022;18:86-8. [PMID: 36694894 DOI: 10.17925/EE.2022.18.2.86] [Reference Citation Analysis]
5 Kawasaki K, Rekhtman N, Quintanal-villalonga Á, Rudin CM. Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. Nat Rev Clin Oncol 2022. [DOI: 10.1038/s41571-022-00696-0] [Reference Citation Analysis]
6 Chen Y, Takahashi Y, Moro T, Tajima T, Sakaguchi Y, Yamamoto T, Yokoyama A, Hijioka S, Sada A, Tabata Y, Ohki R. Metabolic intervention that reduces glucose-insulin signaling suppresses the onset and progression of neuroendocrine tumors.. [DOI: 10.1101/2022.10.21.507065] [Reference Citation Analysis]
7 Castle JT, Levy BE, Chauhan A. Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability. Cancers (Basel) 2022;14:5049. [PMID: 36291833 DOI: 10.3390/cancers14205049] [Reference Citation Analysis]
8 Kooblall KG, Stokes VJ, Shariq OA, English KA, Stevenson M, Broxholme J, Wright B, Lockstone HE, Buck D, Grozinsky-glasberg S, Yates CJ, Thakker RV, Lines KE. miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2. Endocrine-Related Cancer 2022;29:557-568. [DOI: 10.1530/erc-22-0045] [Reference Citation Analysis]
9 Kravchuk EN, Tsoy UA, Sereda SV, Grineva EN. Individual approach in the treatment of prolactinoma in a patient with multiple endocrine neoplasia type 1 syndrome. jour 2022;2:97-102. [DOI: 10.18705/2782-3806-2022-2-4-97-102] [Reference Citation Analysis]
10 Dreijerink KMA, Ozyerli-Goknar E, Koidl S, van der Lelij EJ, van den Heuvel P, Kooijman JJ, Biniossek ML, Rodenburg KW, Nizamuddin S, Timmers HTM. Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity. Epigenetics Chromatin 2022;15:29. [PMID: 35941657 DOI: 10.1186/s13072-022-00461-8] [Reference Citation Analysis]
11 Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2022;12:901435. [DOI: 10.3389/fonc.2022.901435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sharma A, Memon S, Lila AR, Sarathi V, Arya S, Jadhav SS, Hira P, Garale M, Gosavi V, Karlekar M, Patil V, Bandgar T. Genotype-Phenotype Correlations in Asian Indian Children and Adolescents with Primary Hyperparathyroidism. Calcif Tissue Int 2022. [PMID: 35567607 DOI: 10.1007/s00223-022-00985-x] [Reference Citation Analysis]
13 Feng C, Chen H, Huang L, Feng Y, Chang S. The Research Landscape of Multiple Endocrine Neoplasia Type 1 (2000–2021): A Bibliometric Analysis. Front Med 2022;9:832662. [DOI: 10.3389/fmed.2022.832662] [Reference Citation Analysis]
14 Seabrook A, Wijewardene A, De Sousa S, Wong T, Sheriff N, Gill AJ, Iyer R, Field M, Luxford C, Clifton-Bligh R, McCormack A, Tucker K. MEN4, the MEN1 mimicker; a case series of 3 phenotypically heterogenous patients with unique CDKN1B mutations. J Clin Endocrinol Metab 2022:dgac162. [PMID: 35323929 DOI: 10.1210/clinem/dgac162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Aydemir E, Ateş C, Mercan Saridaş F, Hocaoğlu E, Cander S, Öz Gül Ö, Ertürk E, Ersoy C. Evaluation of Insulinoma Cases Presented with Hyperinsulinemic Hypoglycemia: A single-centre Experience. Turkish Journal of Internal Medicine. [DOI: 10.46310/tjim.1073351] [Reference Citation Analysis]
16 Damianse SSP, Nascimento GC, Rocha VCC, Nascimento AGPAC, Gaido NC, Azulay RSS, Dos Santos WC, Rodrigues VP, Quidute ARP, Magalhães M, Faria MDS. The Importance of Periodical Screening for Primary Hyperparathyroidism in a Pituitary Tumor Cohort in Searching Patients with MEN1 and its Genetic Profile. Endocr Pract 2022:S1530-891X(22)00065-9. [PMID: 35247589 DOI: 10.1016/j.eprac.2022.02.010] [Reference Citation Analysis]
17 Jacob M, Rowland D, Lekarev O, Ergun-longmire B. Multiple Endocrine Neoplasia in Childhood: An Update on Diagnosis, Screening, Management and Treatment. Endocrines 2022;3:76-91. [DOI: 10.3390/endocrines3010007] [Reference Citation Analysis]
18 Chanson P, Maiter D. Prolactinoma. The Pituitary 2022. [DOI: 10.1016/b978-0-323-99899-4.00011-1] [Reference Citation Analysis]
19 Newey PJ, Hannan FM, Wilson A, Thakker RV. Genetics of monogenic disorders of calcium and bone metabolism. Clin Endocrinol (Oxf) 2021. [PMID: 34935164 DOI: 10.1111/cen.14644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Auernhammer CJ, Böck S, Westphalen CB, Beyer L, Spitzweg C. Medikamentöse Systemtherapie bei Neuroendokrinen Neoplasien des GastroEnteropankreatischen Systems. Der Nuklearmediziner 2021;44:326-333. [DOI: 10.1055/a-1556-8264] [Reference Citation Analysis]
21 Duan S, Rico K, Merchant JL. Gastrin: From Physiology to Gastrointestinal Malignancies. Function (Oxf) 2022;3:zqab062. [PMID: 35330921 DOI: 10.1093/function/zqab062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Newey PJ. Hereditary Primary Hyperparathyroidism. Endocrinol Metab Clin North Am 2021;50:663-81. [PMID: 34774240 DOI: 10.1016/j.ecl.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 La Salvia A, Sesti F, Grinzato C, Mazzilli R, Tarsitano MG, Giannetta E, Faggiano A. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel) 2021;14:1039. [PMID: 34681263 DOI: 10.3390/ph14101039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Pastorino L, Grillo F, Albertelli M, Ghiorzo P, Bruno W. Insights into Mechanisms of Tumorigenesis in Neuroendocrine Neoplasms. Int J Mol Sci 2021;22:10328. [PMID: 34638668 DOI: 10.3390/ijms221910328] [Reference Citation Analysis]
25 Marini F, Giusti F, Brandi ML. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives. Expert Rev Endocrinol Metab 2021;:1-13. [PMID: 34554891 DOI: 10.1080/17446651.2021.1982382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Marini F, Brandi ML. Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy. Int J Mol Sci 2021;22:7352. [PMID: 34298972 DOI: 10.3390/ijms22147352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Krasnoselskyi МV, Svynarenko АV, Pidchenko NS, Simbirоva AS. Multiple endocrine neoplasia syndrome. УРОЖ 2021;29:150-158. [DOI: 10.46879/ukroj.2.2021.150-158] [Reference Citation Analysis]
28 Marini F, Giusti F, Tonelli F, Brandi ML. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. Int J Mol Sci 2021;22:4041. [PMID: 33919851 DOI: 10.3390/ijms22084041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]